CDT-Backed Sarborg Applies Quantum Computing to Mental Health Drug Discovery
Event summary
- Sarborg applied its patented Signature Intelligence and quantum computing models to mental health and neuropsychiatric drug discovery.
- CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital.
- Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.
- Sarborg is in discussions with pharmaceutical and biotechnology companies, academic institutions, and research organizations regarding potential applications and strategic collaborations.
The big picture
CDT’s backing of Sarborg highlights the growing intersection of quantum computing and biopharmaceutical research. The mental health sector, with its significant unmet needs and high economic costs, represents a strategic opportunity for Sarborg’s proprietary models. The success of these applications could validate the broader potential of quantum computing in drug discovery, potentially attracting more investment and partnerships in the field.
What we're watching
- Technology Validation
- How Sarborg’s quantum computing models will perform in real-world drug discovery applications.
- Partnership Dynamics
- Whether Sarborg can secure strategic collaborations with major pharmaceutical companies.
- Market Expansion
- The pace at which Sarborg can apply its technology to other areas of unmet medical need.